Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Ovid Therapeutics Inc. | Soticlestat (TAK-935/OV935) - (ARCADE) | CDKL5 Deficiency | Phase 2 | Trial Completed | Oral | Genetic Disorder |
| Ovid Therapeutics Inc. | OV101 | Fragile X syndrome | Phase 2 | Trial Discontinued | Oral | Genetic Disorder |
| Oyster Point Pharma Inc. | Varenicline (OC-01) - (OLYMPIA) | Neurotrophic Keratitis (NK) | Phase 2 | Trial Discontinued | Intranasal | Opthalmic |
| Oyster Point Pharma Inc. | Varenicline (OC-01) | Dry eye disease | Phase 2 | Intranasal | Opthalmic | |
| Pacira BioSciences Inc. | EXPAREL | Lower extremity nerve block | Phase 3 | Infiltration or interscalene brachial plexus nerve block | Anesthetic | |
| Pacira BioSciences Inc. | EXPAREL | Lower extremity nerve blocks | Phase 3 | Trial Completed | Infiltration or interscalene brachial plexus nerve block | Anesthetic |
| Pacira BioSciences Inc. | PCRX-201 (enekinragene inzadenovec) - (ASCEND) | Osteoarthritis of the knee | Phase 2 | Enrollment Conclusion | Intratumoral injection | Orthopedic |
| Palatin Technologies Inc. | PL9643 - (MELODY-2 & MELODY-3) | Dry eye disease (DED) | Phase 3 | Trial Planned | Ophthalmic | Opthalmic |
